RIPK2 and cancer: - Stages, recurrence, and patients’ low survival rates- Prevalence of a molecular feature such as mutation of BRAF, hypermutation with microsatellite instability and metastases- Serrated pathway manipulation- Binds to the E-cadherins’s extracellular domain and induces cancer cell proliferation- Promotes autophagy by upregulating CARD3- Regulates microRNA to induce chemotherapy resistance- Inhibits T-cell infiltration and stimulates myeloid-derived immunity